Scarica l'app Stockscreener
29.12
5.16%
1.43
Precedente Chiudi:
$27.69
Aprire:
$27.55
Volume 24 ore:
1.72M
Relative Volume:
1.10
Capitalizzazione di mercato:
$2.57B
Reddito:
-
Utile/perdita netta:
$-151.78M
Rapporto P/E:
-14.14
EPS:
-2.0595
Flusso di cassa netto:
$-136.42M
1 W Prestazione:
+8.33%
1M Prestazione:
+22.92%
6M Prestazione:
-18.45%
1 anno Prestazione:
+100.28%
Intervallo 1D:
$27.01
$29.97
Intervallo di 1 settimana:
$25.56
$29.97
Portata 52W:
$12.59
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
29.12 | 2.38B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | TD Cowen | Buy |
| 2025-06-11 | Iniziato | Jefferies | Hold |
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Mineralys Therapeutics Insider Sold Shares Worth $2,696,322, According to a Recent SEC Filing - marketscreener.com
Mineralys Therapeutics Insider Sold Shares Worth $1,960,601, According to a Recent SEC Filing - marketscreener.com
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
Form 4 Mineralys Therapeutics Inc For: 30 June By Investing.com - Investing.com Canada
Mineralys Therapeutics CEO Jon Congleton sells $1.96m in stock - Investing.com
Mineralys Therapeutics CCO Eric Warren sells $2.7m in shares By Investing.com - Investing.com Australia
Mineralys Therapeutics CCO Eric Warren sells $2.7m in shares - Investing.com UK
Mineralys Therapeutics CEO Jon Congleton sells $1.96m in stock By Investing.com - Investing.com Nigeria
Mineralys Therapeutics (MLYS) CEO sells 75K shares under Rule 10b5-1 plan - Stock Titan
Mineralys (NASDAQ: MLYS) CCO sells shares after option exercise - Stock Titan
Mineralys Therapeutics (MLYS) Form 144 lists 90,730 shares sold and RSU vesting - Stock Titan
Form 144 Mineralys Therapeutics For: 29 June By Investing.com - Investing.com South Africa
Mineralys Therapeutics (NASDAQ: MLYS) flagged sale of 104,124 shares via cashless exercise - Stock Titan
Mineralys Therapeutics, Inc.(NasdaqGS:MLYS) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Mineralys Therapeutics, Inc.(NasdaqGS:MLYS) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell Microcap Index - marketscreener.com
Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell 3000E Index - marketscreener.com
Enterprise value to EBITDA forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
Price to earnings forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
Understanding the Setup: (MLYS) and Scalable Risk - Stock Traders Daily
Price to sales forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
Price to book forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision - AOL.com
MLYS Forecast — Price Target — Prediction for 2027 - TradingView
Mineralys Therapeutics, Inc. Actuals & Estimates (NASDAQ:MLYS) - TradingView
Mineralys Therapeutics, Inc. Actuals & Estimates (BOATS:MLYS) - TradingView
Mineralys Therapeutics Inc (MLYS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mineralys Therapeutics (MLYS) Edges Higher as Shares Hold Above Key SupportSign of Strength - Město Břeclav
Mineralys Therapeutics Inc (MLYS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mineralys Therapeutics Inc (MLYS) Institutional Confidence - TradingKey
Mineralys: Limited Differentiation Makes Lorundrostat A Weak Competitor - Seeking Alpha
Mineralys Therapeutics Inc (MLYS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mineralys Therapeutics Inc (MLYS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mineralys Therapeutics director Karydas sells $75,000 in stock By Investing.com - Investing.com India
Mineralys Therapeutics CMO Rodman sells $350,086 in stock By Investing.com - Investing.com India
Mineralys Therapeutics (MLYS) CMO sells 14,474 shares, exercises options - Stock Titan
Director at Mineralys Therapeutics (MLYS) trades 3,000 shares under 10b5-1 plan - Stock Titan
Mineralys Therapeutics director Karydas sells $75,000 in stock - Investing.com
Mineralys Therapeutics CMO Rodman sells $350,086 in stock - Investing.com
Mineralys Therapeutics Inc (MLYS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mineralys Therapeutics Inc (MLYS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mineralys Therapeutics Inc (MLYS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mineralys Therapeutics Inc (MLYS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mineralys Therapeutics (NASDAQ: MLYS) files Form 144 to sell 4,584 shares - Stock Titan
Mineralys Therapeutics (MLYS) Rule 144: 3,000-share cashless exercise - Stock Titan
Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock - Insider Monkey
The Technical Signals Behind (MLYS) That Institutions Follow - Stock Traders Daily
Mineralys Therapeutics (MLYS) affiliate lists multi-date sales and a 3,542-share exercise - Stock Titan
Mineralys Therapeutics Reports Significant Reductions in Heart Failure Risk Biomarkers Associated with Lorundrostat in Proteomic Analysis - Quiver Quantitative
Mineralys Therapeutics Presents Late-Breaking Data on - GlobeNewswire
Blood protein shifts hint at heart failure pathways for lorundrostat - Stock Titan
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mineralys Therapeutics Inc Azioni (MLYS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Warren Eric | Chief Commercial Officer |
Jun 26 '26 |
Option Exercise |
13.24 |
104,124 |
1,378,602 |
142,524 |
| Warren Eric | Chief Commercial Officer |
Jun 26 '26 |
Sale |
25.90 |
104,124 |
2,696,322 |
38,400 |
0.05%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):